Roquefort Therapeutics PLC Appointment of Strategic & Scientific Advisor
February 14 2022 - 2:00AM
RNS Non-Regulatory
TIDMROQ
Roquefort Therapeutics PLC
14 February 2022
14 February 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Appointment of Strategic & Scientific Advisor
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, is pleased to announce that Professor Trevor M. Jones CBE
FMedSci, has been appointed as advisor to the Board with immediate
effect.
Prof. Jones has had a distinguished career in the pharmaceutical
and biotech industry spanning over 45 years, having previously been
main Board Director for Research & Development at The Wellcome
Foundation (Wellcome plc), where he was responsible for the
development of a number of significant products across several
therapeutic areas attracting reimbursement, as well as OTC
formulations. Prof. Jones also served as a Non-Executive Director
of Allergan Inc from 2004 to 2015 during which time the company
made a number of key acquisitions.
During Prof. Jones career, he has served on the Boards of a
number of other private and publicly listed companies and industry
bodies across the UK, USA and Europe. In particular, he was a
former Director General of the Association of the British
Pharmaceutical Industry where he directed all the activities
related to UK pharmaceutical industry government relations on
behalf of national and international pharmaceutical companies. For
12 years he was a member of The UK Government Regulatory Agency,
The Medicines Commission and Chair of the UK Government Advisory
Group on Genetics Research. He was also a member of the Scientific
Board of the EU Life Sciences Innovative Medicines Initiative
(IMI). More recently, Prof. Jones joined the Board of Ascension as
a Non-Executive Director, helping advise the company on product
development and its commercial activities related to haemophilia
and osteoarthritis. He also serves as an adviser to the UK
Government on public health matters including COVID-19.
Stephen West, Executive Chairman, said:
"I am delighted to welcome Trevor as an Advisor to Roquefort
Therapeutics, where I think his experience will be invaluable to
our team. Trevor's substantial expertise and track record in
driving pre-clinical programmes and value creation in the biotech
sector will help the Company navigate this exciting phase of its
development, as we progress with Lyramid's pre-clinical
programme."
Prof. Trevor Jones CBE FMedSci, Advisor, added:
"I am excited to join Roquefort Therapeutics and be involved in
the promising and compelling work the Company has been doing since
it acquired Lyramid last year. I am fascinated by the therapeutic
potential of Midkine, which has the potential to meet a number of
indications of unmet needs in significant addressable markets,
including cancer, anti-inflammatory and autoimmune diseases."
-Ends-
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company's wholly owned
subsidiary, Lyramid Pty Ltd ("LYRAMID"), is a pre-clinical biotech
company focused on developing first in class Midkine inhibiting RNA
therapeutics drugs for the treatment of cancer, chronic
inflammatory, autoimmune disorder and COVID-19. Recent progress
within mRNA therapeutics has led to a reduction in drug development
timelines and costs, increasing the chance of early value
creation.
Through extensive research resulting in validation through
publication in over 1,000 scientific journals, LYRAMID has
identified the potential to exploit the broad therapeutic potential
of Midkine for a number of clinical indications of unmet needs.
LYRAMID holds the largest global IP portfolio on Midkine. The
Midkine blocking drug development markets have significant global
market potential (in the multi-billion dollars). LYRAMID's
pre-clinical programme is currently underway with an initial focus
on cancer (including immunotherapy resistance.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZFLFFLLLZBBZ
(END) Dow Jones Newswires
February 14, 2022 02:00 ET (07:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024